CME Presentations

Upper Tract Urothelial Carcinoma


Presentations


Speakers

  • Angela B. Smith, MD, MS, FACS

    Angela B. Smith, MD, MS, FACS

    Angela B. Smith, MD, MS, FACS

    Associate Professor of Urology

    Angela B. Smith, MD, MS, FACS, is associate professor at the University of North Carolina (UNC) Department of Urology in Chapel Hill and director of urologic oncology at the UNC Lineberger Comprehensive Cancer Center where she treats GU malignancies, including bladder, prostate and kidney cancer. She has a background in health services research and biostatistics with interests in patient-centered outcomes research, risk stratification, and quality of care for invasive bladder cancer. Dr Smith is assistant secretary of the American Urological Association (AUA) and a member of their Quality Improvement and Patient Safety Committee and is a Bladder Cancer Advocacy Network (BCAN) scientific advisory board member. She received her MD and MS degrees from the University of North Carolina.
  • Phillip M. Pierorazio, MD

    Phillip M. Pierorazio, MD

    Phillip M. Pierorazio, MD

    Associate Professor of Urology and Oncology

    Phillip M. Pierorazio, MD, is associate professor of urology and oncology in the Brady Urological Institute at Johns Hopkins University in Baltimore, Maryland. He has expertise in all malignancies of the urinary tract and performs open and minimally-invasive surgeries of the kidney, bladder, prostate and retroperitoneal lymph node dissection for testicular cancer. He has a special interest in kidney cancer, including partial nephrectomy for early-stage disease and high-risk surgeries for patients with advanced cancers. Dr Pierorazio is on the AUA and NCCN Guidelines Committees for Kidney Cancer, director of the Division of Testicular Cancer and a member of the NCCN Guidelines Committee and works with various testicular cancer advocacy groups around the United States.

CME Information

Novel Treatment Advances for Upper Tract Urothelial Carcinoma (UTUC)


PIM Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Adopt diagnostic and prognostic methods and guidelines to stage and grade (low vs high) UTUC
  • Summarize the benefits and challenges of available treatment options for low-grade UTUC
  • Examine latest clinical data on emerging strategies, such as chemoablation, for low-grade UTUC

Acknowledgement

This activity is supported by an independent educational grant from UroGen Pharma.

Tuition

Complimentary

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

Physician Continuing Education
Live Activity

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Date of Release/Expiration

Live Activity

Tuesday, June 18, 2019 from 10:00am – 11:00am EDT.

Enduring Material

The enduring material will be available from June 18, 2019 to June 18, 2020.

Target Audience

This activity is intended for urologists, medical/genitourinary oncologists, surgeons, and other health care professionals (primary care physicians, physicians-in-training, urology nurses, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with UTUC.

Estimated Time to Complete

This activity consists of one session which should take approximately 1 hour to complete.

Method of Participation

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Faculty Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Presenter

Phillip M. Pierorazio, MD
Consulting Fees: Urogen Pharmaceuticals

Angela B. Smith, MD, MS, FACS
Consulting Fees: Photocure
Other: PCORI Research Funding

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

PlatformQ Health Education, LLC

Agnes Lee
Medical Director
PlatformQ Health Education, LLC

Has nothing to disclose relevant to this activity.

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com.


Technical Support:
For any technical issues or issues with your CME Certificate, please contact UroCareLive at 877-394-1306 or at Support@UroCareLive or OMedLive at 877-394-1306 or at Support@OMedLive.